Genexine’s First-in-Class SOX2 Degrader GX-BP1 Achieves Up to 96% Tumor Growth Inhibition and Prevents Regrowth in Preclinical Studies

Genexine’s First-in-Class SOX2 Degrader GX-BP1 Achieves Up to 96% Tumor Growth Inhibition and Prevents Regrowth in Preclinical Studies Genexine, Inc., a clinical-stage biotechnology firm focused on next-generation therapeutic platforms, has…

Read MoreGenexine’s First-in-Class SOX2 Degrader GX-BP1 Achieves Up to 96% Tumor Growth Inhibition and Prevents Regrowth in Preclinical Studies

Global Healthy Living Foundation to Integrate Walgreens Vaccine Scheduler to Enhance Patient Access and Navigation

Global Healthy Living Foundation to Integrate Walgreens Vaccine Scheduler, Enhancing Patient Access and Transparency The Global Healthy Living Foundation (GHLF) has announced a new collaboration with Walgreens aimed at simplifying…

Read MoreGlobal Healthy Living Foundation to Integrate Walgreens Vaccine Scheduler to Enhance Patient Access and Navigation

Saving Limbs Where Others Fail: Cagent Vascular Reports Landmark Data for Serration Remodeling Therapy™ in Below-the-Ankle Arteries

Advancing Limb Salvage: Cagent Vascular Reports Landmark Peer-Reviewed Evidence Supporting Serration Remodeling Therapy™ in Complex Below-the-Ankle Arteries Cagent Vascular, a recognized innovator in endovascular device technologies, has announced the publication…

Read MoreSaving Limbs Where Others Fail: Cagent Vascular Reports Landmark Data for Serration Remodeling Therapy™ in Below-the-Ankle Arteries

GSK Announces Priority Review and Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Bepirovirsen in Chronic Hepatitis B

GSK Reports U.S. Food and Drug Administration Grants Breakthrough Therapy Designation and Priority Review Acceptance for Bepirovirsen in Chronic Hepatitis B as Potential First-in-Class Treatment Ionis Pharmaceuticals and its partner…

Read MoreGSK Announces Priority Review and Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Bepirovirsen in Chronic Hepatitis B